As a provider of high-quality, cost-effective cellular and digital pathology services, we’re excited to attend the upcoming BioTrinity conference in London. This established event is considered a must-attend for those in the life sciences industry and is known for catalysing growth and promoting in-person engagement.
The conference attracts a diverse audience, including early stage and emerging life sciences R&D companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. With its focused, relevant, and stimulating programme, led by great speakers, the event promises to deliver valuable insights and opportunities for all attendees.
We can’t wait to attend BioTrinity and to engage with the life sciences community in person once again.
Date/Time
25-26th April 2023
Event type
Conference
Attendees
Barbara McManus, Michaela Downie, Tom Ashmore, Morag McFarlane
Attendees
Barbara McManus
Managing Director
As our Managing Director, Barbara is continuing to drive HistologiX’s strategic growth plan supporting biotherapeutic drug development and testing. She ensures the whole team continues to support our Clients’ needs thus building long term collaborative relationships. Barbara also has a focus on identifying opportunities to expand the niche services HistologiX offers.
Barbara began her scientific career within academic research institutes following her graduation from Strathclyde University, before moving into the contract testing industry. Barbara holds more than twenty years of invaluable Client and study management experience within the Life Sciences Sector and has worked for both large multinationals and small business start-ups.
Michaela Downie
Business Development Manager
Michaela is our Business Development Manager, responsible for strengthening relationships with existing clients and identifying new areas to grow the business. She has 20+ years of experience working globally with Biotech and Pharma Clients in Key Account and Business Development positions across the Life Sciences CRO sector.
Michaela began her scientific career at the University of Cambridge as a PostDoc in Dermatology, researching inflammatory skin diseases employing a variety of molecular and histology techniques including IHC and ISH. Michaela holds a PhD in Clinical Biochemistry from the University of Cambridge and a Diplom in Biology from the University of Cologne.
Tom Ashmore
Business Development Executive
Tom’s focus in Business Development involves identifying new business opportunities and acting as the initial point of contact for companies seeking our cellular and digital pathology services. He is fully conversant in the range of services that HistologiX provides, and using his scientific and legal backgrounds, he discusses and helps design projects to meet our Clients’ analytical goals.
After working in PostDoc research roles with a focus on metabolic programming of obesity, diabetes and ageing, Tom trained in Intellectual Property Law in the pharma and biotech sectors. Tom has a 1st Class honours degree in Biochemistry from the University of Nottingham, and both a Masters and PhD from the University of Cambridge.
Dr Morag McFarlane
Chief Executive Officer
Morag is the Niche CRO group CEO and is responsible for the group’s growth strategy. She brings with her experience in start-ups, scaling up and acquisitions.
She founded Tissue Solutions and grew it to a significant player in the tissue supply market, before exiting in 2021. Morag has worked in multiple CROs with over 30 years’ experience in pre-clinical research and drug discovery.
